These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21811775)

  • 41. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Konig H; Holyoake TL; Bhatia R
    Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
    Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
    Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.
    Azam M; Daley GQ
    Mol Diagn Ther; 2006; 10(2):67-76. PubMed ID: 16669605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
    Preyer M; Vigneri P; Wang JY
    PLoS One; 2011 Feb; 6(2):e17020. PubMed ID: 21347248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
    von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
    Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
    Pricl S; Fermeglia M; Ferrone M; Tamborini E
    Mol Cancer Ther; 2005 Aug; 4(8):1167-74. PubMed ID: 16093432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
    Agafonov RV; Wilson C; Otten R; Buosi V; Kern D
    Nat Struct Mol Biol; 2014 Oct; 21(10):848-53. PubMed ID: 25218445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
    Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
    Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.
    White D; Saunders V; Lyons AB; Branford S; Grigg A; To LB; Hughes T
    Blood; 2005 Oct; 106(7):2520-6. PubMed ID: 15956284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
    Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
    Sacha T; Hochhaus A; Hanfstein B; Müller MC; Rudzki Z; Czopek J; Wolska-Smoleń T; Czekalska S; Salamanchuk Z; Jakóbczyk M; Skotnicki AB
    Leuk Res; 2003 Dec; 27(12):1163-6. PubMed ID: 12921956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H; Raj U; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
    O'Hare T; Eide CA; Deininger MW
    Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S120-30. PubMed ID: 17382021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
    Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.